According to Olivier Soula, CEO and co-founder of Adocia: 'Our Chinese partner Tonghua Dongbao reached a major milestone in 2025: the Phase 3 trial involving over 1,000 people with type 2 diabetes confirms the excellent performance of BioChaperone Lispro. For the first time, a prandial insulin has demonstrated superior glycemic control in type 2 diabetic patients across all three daily meals compared to Humalog, one of the world's most widely used prandial insulins'.

Adocia highlighted significant clinical advantages over Humalog: improved long-term glycemic control in patients on metformin or with HbA1c levels below 8.5%, and superior blood glucose control throughout the day and after each meal for the overall population.